| Literature DB >> 19318699 |
K M Venables1, C Brooks, L Linsell, T J Keegan, T Langdon, T Fletcher, M J Nieuwenhuijsen, N E S Maconochie, P Doyle, V Beral, L M Carpenter.
Abstract
OBJECTIVE: To investigate any long term effects on mortality in participants in experimental research related to chemical warfare agents from 1941 to 1989.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19318699 PMCID: PMC3269894 DOI: 10.1136/bmj.b613
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Characteristics of 18 276 Porton Down veterans and 17 600 non-Porton Down veterans. Figures are numbers (percentages) of veterans
| Characteristic | Porton Down veterans | Non-Porton Down veterans |
|---|---|---|
| Service at enlistment: | ||
| Army | 11 407 (62.4) | 10 872 (61.8) |
| Air force | 4026 (22.0) | 3987 (22.7) |
| Navy (and marines) | 2843 (15.6) | 2741 (15.6) |
| Decade of birth: | ||
| Before 1920 | 3742 (20.5) | 3794 (21.6) |
| 1920s | 3515 (19.2) | 3211 (18.2) |
| 1930s | 6088 (33.3) | 5977 (34.0) |
| 1940s or later | 4931 (27.0) | 4618 (26.2) |
| Place of birth: | ||
| England | 14 295 (79.2) | 13 761 (78.9) |
| Wales | 931 (5.2) | 919 (5.3) |
| Scotland | 1785 (9.9) | 1803 (10.3) |
| Northern Ireland | 307 (1.7) | 248 (1.4) |
| Republic of Ireland | 265 (1.5) | 261 (1.5) |
| Overseas | 458 (2.5) | 444 (2.5) |
| Missing | 235 | 164 |
| Age (years) at enlistment: | ||
| <16 | 1237 (6.8) | 1220 (6.9) |
| 16-<18 | 4987 (27.4) | 4290 (24.4) |
| 18-<20 | 6495 (35.7) | 6211 (35.3) |
| 20-<22 | 2270 (12.5) | 2354 (13.4) |
| ≥22 | 3226 (17.7) | 3517 (20.0) |
| Missing | 61 | 8 |
| Period at enlistment*: | ||
| Before second world war | 975 (5.4) | 884 (5.0) |
| During second world war | 5275 (29.0) | 5048 (28.7) |
| After second world war | 7814 (42.9) | 7667 (43.6) |
| After national service | 4151 (22.8) | 3993 (22.7) |
| Missing | 61 | 8 |
| Rank at enlistment: | ||
| Private (or equivalent) | 18 094 (99.3) | 17 438 (99.4) |
| Other | 122 (0.7) | 112 (0.6) |
| Missing | 60 | 50 |
| Duration of service at first visit to Porton Down (years): | ||
| <2 | 8160 (44.8) | NA |
| 2-<3 | 3087 (17.0) | NA |
| 3-<5 | 3572 (19.6) | NA |
| 5-<10 | 2341 (12.9) | NA |
| ≥10 | 1055 (5.8) | NA |
| Missing | 61 | |
| Total duration of service (years)†: | ||
| <2 | 438 (2.4) | 2771 (15.8) |
| 2-<3 | 2830 (15.6) | 3406 (19.4) |
| 3-<5 | 2823 (15.6) | 2728 (15.5) |
| 5-<10 | 7011 (38.6) | 5565 (31.6) |
| ≥10 | 5043 (27.8) | 3117 (17.7) |
| Missing | 131 | 13 |
| Vital status at 31 December 2004: | ||
| Alive | 10 409 (57.0) | 10 222 (58.1) |
| Deceased | 7306 (40.0) | 6900 (39.2) |
| Follow-up censored at: | ||
| Discharge from services | 438 (2.4) | 346 (2.0) |
| Emigration | 68 (0.4) | 69 (0.4) |
| Other | 55 (0.3) | 63 (0.4) |
NA=not applicable.
*Second world war dates taken as 1 September 1939 to 30 April 1945; national service dates taken as 1 May 1945 to 31 December 1960.
†Includes 148 Porton Down veterans, and 132 non-Porton Down veterans still serving at time of data abstraction.
Summary of exposures in 18 276 Porton Down veterans, 1941-89
| No (%) of veterans | |
|---|---|
| No of tests: | |
| 1 | 2173 (11.9) |
| 2-5 | 4161 (22.8) |
| 6-9 | 3814 (20.9) |
| 10-14 | 3080 (16.9) |
| ≥15 | 4075 (22.3) |
| None | 973 (5.3) |
| Decade of first test*: | |
| 1940s | 6504 (35.6) |
| 1950s | 6097 (33.4) |
| 1960s | 2260 (12.4) |
| 1970s | 1966 (10.8) |
| 1980s | 1449 (7.9) |
| No of chemical tests†: | |
| ≥1 | 16 686 (91.3) |
| None | 1590 (8.7) |
| Type of chemical test†: | |
| Vesicant: | |
| Any | 10 539 (57.7) |
| Sulphur mustard‡ | 10 273 (56.2) |
| Lewisite | 1745 (9.5) |
| Nitrogen mustard | 1183 (6.5) |
| Nerve agent: | |
| Any | 3597 (19.7) |
| Sarin | 2980 (16.3) |
| Other chemical: | |
| Any | 11 925 (65.2) |
| CS | 1328 (7.3) |
| CR | 1175 (6.4) |
| Pralidoxime | 1696 (9.3) |
| Atropine | 1577 (8.6) |
*Date of first visit for those with no test data.
†Includes 17 303 veterans for whom type of test could be determined.
‡Includes mustard sensitivity tests.

Fig 1 Overlap of exposure groups in 16 686 Porton Down veterans (excludes 1590 not recorded as exposed to any chemical)
All cause mortality in Porton Down veterans and non-Porton Down veterans compared with national mortality rates according to service at enlistment. Standardised mortality ratios (95% confidence intervals) adjusted for calendar year and age group
| Porton Down veterans | Non-Porton Down veterans | ||||
|---|---|---|---|---|---|
| Observed deaths* | Standardised mortality ratio | Observed deaths* | Standardised mortality ratio | ||
| All veterans | 6885 | 0.88 (0.85 to 0.90) | 6582 | 0.82 (0.80 to 0.84) | |
| Service at enlistment: | |||||
| Army | 5100 | 0.88 (0.86 to 0.91) | 4892 | 0.84 (0.81 to 0.86) | |
| Air force | 965 | 0.77 (0.72 to 0.82) | 929 | 0.72 (0.68 to 0.77) | |
| Navy (and marines) | 820 | 0.97 (0.90 to 1.03) | 761 | 0.88 (0.81 to 0.94) | |
*Includes deaths registered in UK.
Cause specific mortality in Porton Down veterans compared with non-Porton Down veterans. Rate ratios (95% confidence intervals) with and without adjustment for age group and calendar period
| Observed deaths | Rate ratio | ||||
|---|---|---|---|---|---|
| Porton Down veterans | Non-Porton Down veterans | Unadjusted | Adjusted (95% CI) | ||
| All causes (ICD-10 code) | |||||
| Total | 7306 | 6900 | 1.03 | 1.06*** (1.03 to 1.10) | |
| All deaths registered in UK (A00-Z99) | 6885 | 6582 | 1.02 | 1.06** (1.02 to 1.09) | |
| All deaths not registered in UK | 421 | 318 | 1.29*** | 1.26** (1.09 to 1.46) | |
| Infectious and parasitic (A00-B99) | 66 | 43 | 1.49 | 1.57* (1.07 to 2.29) | |
| Malignant neoplasms: | |||||
| All (C00-97) | 2093 | 2041 | 1.00 | 1.03 (0.97 to 1.10) | |
| Upper aerodigestive (C00-14, C30-32) | 59 | 57 | 1.01 | 1.03 (0.71 to 1.48) | |
| Oesophagus (C15) | 86 | 99 | 0.85 | 0.87 (0.65 to 1.16) | |
| Stomach (C16) | 152 | 137 | 1.08 | 1.13 (0.89 to 1.42) | |
| Intestine and rectum (C17-20) | 198 | 188 | 1.02 | 1.06 (0.87 to 1.30) | |
| Pancreas (C25) | 83 | 89 | 0.91 | 0.94 (0.70 to 1.27) | |
| Trachea, bronchus, and lung (C33,C34) | 785 | 726 | 1.05 | 1.09 (0.98 to 1.21) | |
| Melanoma and other skin (C43,C44) | 26 | 31 | 0.82 | 0.83 (0.49 to 1.40) | |
| Prostate (C61) | 146 | 149 | 0.95 | 1.01 (0.80 to 1.27) | |
| Urinary tract (C64-68) | 122 | 126 | 0.94 | 0.98 (0.76 to 1.26) | |
| Brain and other central nervous system (C71, C72) | 46 | 58 | 0.77 | 0.78 (0.53 to 1.15) | |
| All lymphatic and haematopoietic (C81-96) | 128 | 132 | 0.94 | 0.96 (0.76 to 1.23) | |
| All other malignant neoplasms† | 262 | 249 | 1.02 | 1.06 (0.89 to 1.26) | |
| In situ, benign, and unspecified neoplasms (D10-48) | 25 | 42 | 0.58* | 0.60* (0.37 to 0.99) | |
| Endocrine, nutritional, and metabolic (E00-90) | 65 | 70 | 0.90 | 0.94 (0.67 to 1.31) | |
| Mental and behavioural (F00-99) | 53 | 51 | 1.01 | 1.08 (0.73 to 1.59) | |
| Nervous system (G00-99) | 104 | 132 | 0.77 | 0.80 (0.62 to 1.03) | |
| Circulatory system: | |||||
| All (I00-99) | 3007 | 2851 | 1.03 | 1.07* (1.01 to 1.12) | |
| Ischaemic heart diseases (I20-25) | 2021 | 1884 | 1.04 | 1.08* (1.01 to 1.15) | |
| Cerebrovascular diseases (I60-69) | 504 | 501 | 0.98 | 1.03 (0.91 to 1.17) | |
| All other circulatory (I00-19, I26-59, I70-99) | 482 | 466 | 1.01 | 1.05 (0.93 to 1.20) | |
| Respiratory system: | |||||
| All (J00-99) | 694 | 662 | 1.02 | 1.07 (0.96 to 1.19) | |
| Chronic lower respiratory tract (J40-47) | 426 | 417 | 0.99 | 1.04 (0.91 to 1.19) | |
| All other respiratory (J00-39, J48-99) | 268 | 245 | 1.06 | 1.12 (0.94 to 1.33) | |
| Digestive system (K00-93) | 218 | 206 | 1.03 | 1.05 (0.87 to 1.27) | |
| Musculoskeletal system and connective tissue (M00-99) | 23 | 27 | 0.83 | 0.87 (0.50 to 1.51) | |
| Genitourinary system (N00-99) | 81 | 57 | 1.38 | 1.46* (1.04 to 2.04) | |
| All external causes (S00-T98, V01-Y98) | 341 | 284 | 1.17 | 1.17* (1.00 to 1.37) | |
| All other UK deaths with ICD code‡ | 44 | 39 | 1.10 | 1.12 (0.73 to 1.73) | |
| All other UK deaths with no ICD code | 71 | 77 | 0.90 | 0.92 (0.67 to 1.27) | |
†C21-24, C26-29, C37-41, C45-50, C60, C62, C63, C69, C70, C73-80, C97.
‡D50-89, H00-95, L00-99, Q00-99, R00-99, U00-89, Z00-99.
*P<0.05; **P<0.01; ***P<0.001.
All cause mortality in Porton Down veterans compared with non-Porton Down veterans according to time since first test. Rate ratios adjusted for five year age group and five year calendar period
| Years since first test | All deaths | Deaths registered in UK | Deaths not registered in UK | |||||
|---|---|---|---|---|---|---|---|---|
| Deaths | Rate ratio (95% CI) | Deaths | Rate ratio (95% CI) | Deaths | Rate ratio (95% CI) | |||
| <2 | 170 | 1.14 (0.91 to 1.42) | 34 | 1.11 (0.68 to 1.83) | 136 | 1.14 (0.89 to 1.47) | ||
| 2-<5 | 144 | 1.29* (1.01 to 1.66) | 39 | 0.91 (0.59 to 1.40) | 105 | 1.53** (1.13 to 2.09) | ||
| 5-<10 | 74 | 1.04 (0.76 to 1.43) | 68 | 1.01 (0.73 to 1.41) | 6 | 1.54 (0.44 to 5.40) | ||
| 10-<20 | 282 | 1.04 (0.88 to 1.22) | 270 | 1.03 (0.87 to 1.23) | 12 | 1.08 (0.48 to 2.42) | ||
| 20-<40 | 2579 | 1.07** (1.02 to 1.13) | 2535 | 1.07** (1.01 to 1.13) | 44 | 1.20 (0.77 to 1.87) | ||
| ≥40 | 4057 | 1.05** (1.01 to 1.10) | 3939 | 1.05** (1.00 to 1.10) | 118 | 1.28 (0.97 to 1.68) | ||
| Total | 7306 | 1.06*** (1.03 to 1.10) | 6885 | 1.06** (1.02 to 1.09) | 421 | 1.26** (1.09 to 1.46) | ||
*P<0.05, **P<0.01, ***P<0.001.

Fig 2 Rate ratios for cause specific mortality in Porton Down veterans included in test(s) involving vesicant(s) compared with non-Porton Down veterans, adjusted for age and calendar period. Rate ratio estimates are represented by box with size inversely proportional to variance. Vertical dotted line shows estimate for all deaths. For clarity, only rows for major ICD chapter headings are presented

Fig 3 Rate ratios for cause specific mortality in Porton Down veterans included in test(s) involving nerve agent(s) compared with non-Porton Down veterans, adjusted for age and calendar period. Rate ratio estimates are represented by box with size inversely proportional to variance. Vertical dotted line shows estimate for all deaths. For clarity, only rows for major ICD chapter headings are presented

Fig 4 Rate ratios for cause-specific mortality in Porton Down veterans included in test(s) involving any other chemical(s) compared with non-Porton Down veterans, adjusted for age and calendar period. Rate ratio estimates are represented by box with size inversely proportional to variance. Vertical dotted line shows estimate for all deaths. For clarity, only rows for major ICD chapter headings are presented
Mortality by selected underlying causes (ICD-10 code) for Porton Down veterans with high recorded levels of exposure to specific chemicals, relative to non-Porton Down veterans. Rate ratios adjusted for age group and calendar period (95% CI)
| Chemical and indicator of high exposure | No of deaths | Adjusted rate ratio (95% CI) |
|---|---|---|
| Dermal ≥10.63 mg: | ||
| Upper aerodigestive cancers (C00-C14, C30-C32) | 10 | 0.76 (0.34 to 1.51) |
| Cancers of trachea, bronchus, and lung (C33, C34) | 195 | 0.99 (0.84 to 1.16) |
| Diseases of circulatory system (I00-I99) | 804 | 1.04 (0.96 to 1.12) |
| Chronic lower respiratory tract diseases (J40-J47) | 118 | 0.99 (0.81 to 2.07) |
| All external causes (S00-T98, V01-Y98) | 69 | 1.22 (0.93 to 1.60) |
| Dermal vesicle: | ||
| Upper aerodigestive cancers (C00-C14, C30-C32) | 17 | 1.19 (0.68 to 2.07) |
| Cancers of trachea, bronchus, and lung (C33, C34) | 259 | 1.12 (0.92 to 1.29) |
| Diseases of circulatory system (I00-I99) | 1004 | 1.11** (1.01 to 1.12) |
| Chronic lower respiratory tract diseases (J40-J47) | 162 | 1.13 (0.94 to 1.36) |
| All external causes (S00-T98, V01-Y98) | 80 | 1.35* (1.01 to 1.75) |
| Dermal ≥13.69 mg: | ||
| Cancers of trachea, bronchus, and lung (C33, C34) | 27 | 1.10 (0.75 to 1.61) |
| Melanoma and other skin cancers (C43, C44) | 1 | 1.86 (0.04 to 12.83) |
| Diseases of circulatory system (I00-I99) | 109 | 1.14 (0.94 to 1.38) |
| Dermal vesicle: | ||
| Cancers of trachea, bronchus, and lung (C33, C34) | 73 | 1.25 (0.98 to 1.60) |
| Melanoma and other skin cancers (C43, C44) | 0 | 0.00 (0.00 to 3.13) |
| Diseases of circulatory system (I00-I99) | 261 | 1.14* (1.01 to 1.30) |
| Dermal ≥23.73 mg: | ||
| Melanoma and other skin cancers (C43, C44) | 2 | 3.50 (0.37 to 16.21) |
| All lymphatic and haematopoetic (C81-C96) | 3 | 0.83 (0.17 to 2.53) |
| Dermal vesicle: | ||
| Melanoma and other skin cancers (C43, C44) | 1 | 1.65 (0.04 to 11.42) |
| All lymphatic and haematopoetic (C81-C96) | 1 | 0.26 (0.01 to 1.52) |
| Air ≥14.99 mg.min/m3: | ||
| Diseases of circulatory system (I00-I99) | 61 | 1.22 (0.94 to 1.58) |
| Cholinesterase fall ≥30%: | ||
| Diseases of circulatory system (I00-I99) | 99 | 1.18 (0.96 to 1.45) |
| Diseases of genitourinary system (N00-N99) | 2 | 5.83 (0.64 to 25.00) |
*P<0.05, **P<0.01.